Akoya Biosciences, Inc. (AKYA) said it expects fourth quarter revenue to be between $25.5 million and $26.5 million, as compared to $21.2 million a year ago. For fiscal 2023, the company expects revenue to be between $95.
MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were.
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.